SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-23-211441
Filing Date
2023-08-14
Accepted
2023-08-14 07:10:28
Documents
14
Period of Report
2023-08-14
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d517610d8k.htm   iXBRL 8-K 25387
2 EX-99.1 d517610dex991.htm EX-99.1 43794
6 GRAPHIC g517610g0814005635987.jpg GRAPHIC 3604
  Complete submission text file 0001193125-23-211441.txt   205126

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA grtx-20230814.xsd EX-101.SCH 2854
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE grtx-20230814_lab.xml EX-101.LAB 17979
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE grtx-20230814_pre.xml EX-101.PRE 11261
8 EXTRACTED XBRL INSTANCE DOCUMENT d517610d8k_htm.xml XML 3346
Mailing Address 45 LIBERTY BLVD. SUITE 230 MALVERN PA 19355
Business Address 45 LIBERTY BLVD. SUITE 230 MALVERN PA 19355 610-725-1500
Galera Therapeutics, Inc. (Filer) CIK: 0001563577 (see all company filings)

IRS No.: 461454898 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39114 | Film No.: 231166200
SIC: 2834 Pharmaceutical Preparations